Clinical trials: Lung Fibrosis Interstitial
Asthma, Chronic Obstructive Pulmonary Disease
A Study of Patients With Chronic Disease
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF
- Trial name
- NCT04263727
- Where
- 5 sites in United States
- Volunteers
- 579 people
- Sponsor
- Target PharmaSolutions, Inc.
Idiopathic Pulmonary Fibrosis
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.
- Trial name
- QUALIFY IPF (NCT03710824)
- Testing
- Nintedanib
- Where
- 10 sites in Greece
- Volunteers
- 180 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
- Trial name
- IPF (NCT06764862)
- Testing
- HSK44459 dose 1, HSK44459 dose 2, HSK44459 dose 3
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Idiopathic Pulmonary Fibrosis
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
To evaluate the safety and tolerability of nalbuphine ER tablets in the study population and to evaluate the effect of NAL ER tablets on the mean daytime cough frequency (coughs per hour) at Day 22 (dose 162 mg BID) as compared…
- Trial name
- CANAL (NCT04030026)
- Testing
- NAL ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Trevi Therapeutics
Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT06422884
- Testing
- ENV-101
- Where
- 78 sites in Argentina, Australia and 12 more
- Volunteers
- 213 people
- Sponsor
- Endeavor Biomedicines, Inc.
Lung Cancer, Lung Infection
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules.
- Conditions
- Lung Cancer, Lung Infection, COPD, Bronchitis
- Trial name
- NCT06528418
- Testing
- Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- ChromX Health
Idiopathic Pulmonary Fibrosis
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
- Trial name
- NCT06097260
- Testing
- PLN-74809
- Where
- 268 sites in United States, Argentina and 23 more
- Volunteers
- 320 people
- Sponsor
- Pliant Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis (IPF)
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12…
- Trial name
- NCT05938920
- Testing
- INS018_055
- Where
- 22 sites in China
- Volunteers
- 71 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Idiopathic Pulmonary Fibrosis
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
- Trial name
- ELEVATE (NCT05321420)
- Testing
- Pirfenidone, Deupirfenidone
- Where
- 103 sites in United States, Argentina and 12 more
- Volunteers
- 240 people
- Sponsor
- PureTech
COVID-19, Long COVID
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe…
- Conditions
- COVID-19, Long COVID, Pulmonary Fibrosis, Post-acute Respiratory Complications of COVID-19
- Trial name
- NCT04482595
- Testing
- BIO 300 Oral Suspension
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Humanetics Corporation
Idiopathic Pulmonary Fibrosis
A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis
This trial was performed in patients with idiopathic pulmonary fibrosis (IPF) to evaluate the clinical efficacy and safety of different doses of TDI01 Suspension, compared with control, for the treatment of patients with IPF.
- Trial name
- NCT06102083
- Testing
- TDI01 suspension
- Volunteers
- 120 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Pulmonary Fibrosis
Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)
The purpose of this study is to determine whether NAC added to prednisone, and azathioprine has a better effect on lung function, radiology and clinical condition than placebo + prednisone in combination with azathioprine after 6…
- Trial name
- IFIGENIA (NCT00639496)
- Testing
- n-acetylcysteine
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 184 people
- Sponsor
- Zambon SpA
Healthy Volunteers
A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
The purpose of the study is to assess the effects of BMS-986278 on Drospirenone (DRSP) and Ethinyl Estradiol (EE) when administered as a combined oral contraceptive in healthy female participants.
- Trial name
- NCT05985590
- Testing
- BMS-986278, Drospirenone/Ethinyl Estradiol
- Where
- Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise…
- Trial name
- NCT02803580
- Where
- 18 sites in Italy
- Volunteers
- 209 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
This is a randomized, open-label, 2-treatment, 2-period, crossover steady state study conducted to evaluate the comparative bioavailability/bioequivalence of pirfenidone after multi-dose administration of EXCL-100 at doses of…
- Trial name
- NCT05428150
- Testing
- Esbriet 267 MG Oral Capsule, EXCL-100, 600 MG Oral Tablet
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Excalibur Pharmaceuticals, Inc.
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.
- Trial name
- NCT01266135
- Testing
- QAX576
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Fibroses, Pulmonary
Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19
A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.
- Trial name
- NCT04645368
- Testing
- bovhyaluronidase azoxymer
- Where
- 15 sites in Russia
- Volunteers
- 160 people
- Sponsor
- NPO Petrovax
Idiopathic Pulmonary Fibrosis
A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Study GIPF-002 is a phase 2 study designed to characterize the biologic and clinical effects of IFN-g 1b. The objective of the Study is to characterize the biologic and clinical effects of IFN-g 1b administered to patients with…
- Trial name
- NCT00047658
- Testing
- Interferon-gamma 1b
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- InterMune
Idiopathic Pulmonary Fibrosis
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018_055 in healthy…
- Trial name
- NCT05154240
- Testing
- INS018_055
- Where
- New Zealand
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- InSilico Medicine Hong Kong Limited
Pulmonary Hypertension, Interstitial Lung Disease
A Study of Mosliciguat in PH-ILD
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
- Trial name
- PHocus (NCT06635850)
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 85 sites in United States, Argentina and 18 more
- Volunteers
- 135 people
- Sponsor
- Pulmovant, Inc.